Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Show full item record



Permalink

http://hdl.handle.net/10138/305726

Citation

EAS Familial Hypercholestero & EAS Familial Hypercholesterolaemia 2018 , ' Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) ' , Atherosclerosis , vol. 277 , pp. 234-255 . https://doi.org/10.1016/j.atherosclerosis.2018.08.051

Title: Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Author: EAS Familial Hypercholestero; EAS Familial Hypercholesterolaemia
Date: 2018-10
Language: eng
Number of pages: 22
Belongs to series: Atherosclerosis
ISSN: 0021-9150
URI: http://hdl.handle.net/10138/305726
Abstract: Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in similar to 2/3 countries. Lipoprotein-apheresis is offered in similar to 60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
Subject: Familial hypercholesterolaemia
Primary dyslipidaemia
FHSC
CORONARY-ARTERY-DISEASE
DEFECTIVE APOLIPOPROTEIN B-100
CARDIOVASCULAR RISK-FACTORS
SAFEHEART REGISTRY
GENERAL-POPULATION
NATIONWIDE SURVEY
MOLECULAR-GENETICS
LDL-RECEPTOR
FOLLOW-UP
PREVALENCE
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0021915018313595_main.pdf 4.371Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record